Apogee Therapeutics, Inc. (APGE)
| Market Cap | 10.11B +389.6% |
| Revenue (ttm) | n/a |
| Net Income | -294.37M |
| EPS | -3.91 |
| Shares Out | 75.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,060,397 |
| Open | 134.60 |
| Previous Close | 134.65 |
| Day's Range | 134.58 - 134.72 |
| 52-Week Range | 34.40 - 134.88 |
| Beta | 0.34 |
| Analysts | Hold |
| Price Target | 130.53 (-3.09%) |
| Earnings Date | Aug 10, 2026 |
About APGE
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for APGE stock is "Hold." The 12-month stock price target is $130.53, which is a decrease of -3.09% from the latest price.
News
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive ...
Apogee Therapeutics Earnings release: Q2 2026
Apogee Therapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Apogee Therapeutics Quarterly report: Q2 2026
Apogee Therapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on August 6, 2026, providing details for shareholder voting and corporate governance matters.
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon...
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on July 13, 2026, providing details for shareholder voting and corporate governance matters.
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on July 2, 2026, providing details for shareholder voting and corporate governance matters.
Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underly...
AbbVie's $11 Billion Immunology Bet
In this week's edition of InnovationRx, we look at AbbVie's new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more. To get ...
Apogee Therapeutics downgraded to Hold from Buy at Stifel
Stifel downgraded Apogee Therapeutics (APGE) to Hold from Buy with a price target of $135, up from $133, after the company entered into an agreement to be acquired by AbbVie…
Apogee Therapeutics downgraded to Neutral from Outperform at Mizuho
Mizuho analyst Joseph Catanzaro downgraded Apogee Therapeutics (APGE) to Neutral from Outperform with a price target of $135, up from $110, after the company entered into an agreement to be…
Apogee Therapeutics downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Apogee Therapeutics (APGE) to Hold from Buy with no price target. The firm said it is “sad to see Apogee go,” but the timing post critical Phase…
Apogee Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded Apogee Therapeutics (APGE) to Neutral from Buy after the company agreed to be acquired by AbbVie (ABBV) for $135.11 per share in cash.
Apogee Therapeutics price target raised to $135 from $97 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Apogee Therapeutics (APGE) to $135 from $97 and keeps a Sector Perform rating on the shares after AbbVie (ABBV)…
Apogee Therapeutics moved to No Rating at BofA
BofA moved to No Rating on Apogee Therapeutics (APGE) after the company agreed to be acquired by AbbVie (ABBV) for $135.11 per share in cash. AbbVie sees strategic alignment with…
Apogee Therapeutics downgraded to Neutral from Buy at Citi
Citi analyst Geoff Meacham downgraded Apogee Therapeutics (APGE) to Neutral from Buy with a price target of $135, up from $125, citing the all-cash acquisition by AbbVie for $135.11 per…
Apogee Therapeutics downgraded to Neutral from Buy at UBS
UBS downgraded Apogee Therapeutics (APGE) to Neutral from Buy with a price target of $135.11, up from $100, citing the proposed acquisition by Abbvie. UBS views the price paid as…
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
Clear Street reiterated a Buy rating and $53 price target on Evommune (EVMN), saying Abbvie’s (ABBV) proposed acquisition of Apogee (APGE) provides a positive readthrough to Evommune’s pipeline. In pa...
Apogee Therapeutics downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst David Hoang downgraded Apogee Therapeutics (APGE) to Hold from Buy with a $135 price target after the company agreed to be acquired by AbbVie (ABBV) for $135.11…
Apogee Therapeutics rises 46.8%
Apogee Therapeutics (APGE) is up 46.8%, or $42.26 to $132.64.
Apogee Therapeutics downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum downgraded Apogee Therapeutics (APGE) to Hold from Buy with a $135.11 price target after the company agreed to be acquired by AbbVie (ABBV) for $135.11 per share in cash.
Apogee Therapeutics downgraded to Neutral from Outperform at Wedbush
Wedbush analyst David Nierengarten downgraded Apogee Therapeutics (APGE) to Neutral from Outperform with a $135 price target after the company agreed to be acquired by AbbVie (ABBV) for $135.11 per…